Skip to content
★ Sign in to follow
Total declarations
67
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (46 ops.)
€17.8M

Latest filing published 04 Mar 2026 for Kymera Therapeutics, Inc..

Insider track record

Disclosed buys
0
Disclosed sells
46

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Jared Gollob: trading record in brief

Jared Gollob (senior executive) discloses dealings in Kymera Therapeutics, Inc. to SEC (Form 4). We count 67 filings; the first trade dates from 17 February 2021 and the latest from 4 March 2026.

Sales make up the whole of the open-market record (46 sales, €17.8M). Besides market trades, the filings include 5 share grants and 16 option exercises. Since January 2026: no purchases and 7 sales on the market.

The record was last updated on 4 March 2026 with an open-market sale (€113k) in Kymera Therapeutics, Inc. Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Jared Gollob

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations13 total

13 of 13 declarations